Finding assets, creating spin-outs, commercialising cancer therapies

Learn more

Need for improvement in oncology drug development success rates

Despite progress in improving clinical outcomes for a range of different cancers, a persistently high failure rate in late-stage clinical development exists in this field. By adopting strict criteria early in the development process and focusing on patient sub-group approaches, Cumulus seeks to identify and prioritise those assets and programs that hold the highest potential for clinical success. This has the dual effect of reducing both the late-stage clinical failure rates as well as the high sunk costs that accompany this reality.

Why Oncology

Driving oncology innovation

Cumulus Oncology connects the dots between oncology research, drug discovery, development, commercialisation and value creation to accelerate drug development programs, create new companies, and co-develop or license attractive assets/targets in oncology.

Finding
assets

Creating
spin-outs

Commercialising
cancer therapies

Cumulus works with asset holders from various backgrounds (both academic and commercial) to ensure the best science is moved forward effectively. We use a ‘one team – multiple companies/projects’ approach, enabling through a highly efficient deployment of resources and capital.

About us Our model

Who we are

We bring together scientific experts, entrepreneurs, investment specialists, leading drug discovery, drug development and commercialisation professionals all committed to one common goal: to accelerate oncology innovation into world changing impact. Cumulus puts its expertise and entrepreneurship at the heart of biotech company creation to drive patient benefit and shareholder value.

Our team

We are hiring

Want to be part of a mission-led company in oncology drug development?